Role of the Macrophage in Developmentally Programmed NAFLD

巨噬细胞在发育程序性 NAFLD 中的作用

基本信息

项目摘要

Specific Aim 1. Test the hypothesis that maternal WD during gestation and lactation regulates offspring myeloid cell function through distinct metabolic and/or transcriptional mechanisms that accelerate NAFLD risk across the offspring lifespan. 1a) We will test if WD during gestation or lactation induces changes in number, activation state, or functional responses of fetal liver monocytes (Mo)/Mφ and hematopoietic stem and progenitor cells (HSPCs) or adult offspring liver Mφ and if this can be rescued by cross-fostering to a chow (CH)- fed dam. Liver histology and metabolic phenotyping will be used to evaluate severity of NAFLD and metabolic adaptations at 16 wks of age. 1b) We will profile metabolites and glycolytic/TCA cycle respiratory activity in offspring liver Mφ and BMDM to test for re-programming of immunometabolism. 1c) We will determine the impact of maternal WD exposure on transcriptional and epigenetic adaptations in isolated liver Mo/Mφ and BMDMs in early life and during adulthood. Specific Aim 2. Test the hypothesis that decreased AHR signaling provides a mechanistic link between maternal WD dysbiosis, Mφ metabolic reprogramming, and NAFLD risk. 2a) We will supplement WD-fed dams with an indole-based AHR agonist to determine if restoring AHR signaling protects against maternal WD-induced myeloid dysfunction in offspring. 2b) We will profile transcriptional and epigenetic adaptations in liver Mo/Mφ in WD-exposed offspring with myeloid deletion (KO) of AHR and assess for Mφ functional changes and NAFLD progression. Specific Aim 3. Test the hypothesis that dietary PQQ promotes gut microbial metabolism of indoles that preserve Mφ function in offspring exposed to maternal WD. 3a) We will test if PQQ-exposed microbes transferred to CH-fed GF dams during gestation or lactation increases bacterial production of indoles in offspring.
具体目标验证母体妊娠和哺乳期WD通过不同的代谢和/或转录机制调节后代髓细胞功能的假设,从而加速后代一生中NAFLD的风险。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Pyrroloquinoline-Quinone Is More Than an Antioxidant: A Vitamin-like Accessory Factor Important in Health and Disease Prevention.
  • DOI:
    10.3390/biom11101441
  • 发表时间:
    2021-09-30
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Jonscher KR;Chowanadisai W;Rucker RB
  • 通讯作者:
    Rucker RB
SRI 2023: Scientific Program & Abstracts.
SRI 2023:科学计划
Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms.
  • DOI:
    10.3390/nu12103166
  • 发表时间:
    2020-10-16
  • 期刊:
  • 影响因子:
    5.9
  • 作者:
    Mandala A;Janssen RC;Palle S;Short KR;Friedman JE
  • 通讯作者:
    Friedman JE
Role of Hepatic Aryl Hydrocarbon Receptor in Non-Alcoholic Fatty Liver Disease.
  • DOI:
    10.3390/receptors2010001
  • 发表时间:
    2023-03
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Patil NY;Friedman JE;Joshi AD
  • 通讯作者:
    Joshi AD
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JACOB E FRIEDMAN其他文献

JACOB E FRIEDMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JACOB E FRIEDMAN', 18)}}的其他基金

Center for Indigenous Resilience, Culture, and Maternal Health Equity
土著复原力、文化和孕产妇健康公平中心
  • 批准号:
    10748847
  • 财政年份:
    2023
  • 资助金额:
    $ 51.18万
  • 项目类别:
Understanding the metabolic pathology of pediatric obesity and NAFLD
了解儿童肥胖和 NAFLD 的代谢病理学
  • 批准号:
    10612479
  • 财政年份:
    2022
  • 资助金额:
    $ 51.18万
  • 项目类别:
Understanding the metabolic pathology of pediatric obesity and NAFLD
了解儿童肥胖和 NAFLD 的代谢病理学
  • 批准号:
    10453952
  • 财政年份:
    2022
  • 资助金额:
    $ 51.18万
  • 项目类别:
Maternal Obesity and Pediatric NAFLD: Fetal Origins and Long-term outcomes in Non Human Primates
母亲肥胖和儿童 NAFLD:非人类灵长类动物的胎儿起源和长期结果
  • 批准号:
    10646292
  • 财政年份:
    2021
  • 资助金额:
    $ 51.18万
  • 项目类别:
Maternal Obesity and Pediatric NAFLD: Fetal Origins and Long-term outcomes in Non Human Primates
母亲肥胖和儿童 NAFLD:非人类灵长类动物的胎儿起源和长期结果
  • 批准号:
    10375910
  • 财政年份:
    2021
  • 资助金额:
    $ 51.18万
  • 项目类别:
Role of the Macrophage in Developmentally Programmed NAFLD
巨噬细胞在发育程序性 NAFLD 中的作用
  • 批准号:
    10206128
  • 财政年份:
    2020
  • 资助金额:
    $ 51.18万
  • 项目类别:
The Impact of Maternal Health and Diet on Development of Fetal Metabolic Systems
母亲健康和饮食对胎儿代谢系统发育的影响
  • 批准号:
    8703085
  • 财政年份:
    2010
  • 资助金额:
    $ 51.18万
  • 项目类别:
The Impact of Maternal Health and Diet on Development of Fetal Metabolic Systems
母亲健康和饮食对胎儿代谢系统发育的影响
  • 批准号:
    8053113
  • 财政年份:
    2010
  • 资助金额:
    $ 51.18万
  • 项目类别:
The Impact of Maternal Health and Diet on Development of Fetal Metabolic Systems
母亲健康和饮食对胎儿代谢系统发育的影响
  • 批准号:
    8147743
  • 财政年份:
    2010
  • 资助金额:
    $ 51.18万
  • 项目类别:
METABOLIC CORE
代谢核心
  • 批准号:
    8016442
  • 财政年份:
    2010
  • 资助金额:
    $ 51.18万
  • 项目类别:

相似海外基金

Development of palladium-catalyzed novel organic transformations of silylated allyl acetates
钯催化的硅烷化乙酸烯丙酯新型有机转化的开发
  • 批准号:
    18K05101
  • 财政年份:
    2018
  • 资助金额:
    $ 51.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Biosynthesis of Methylketones and 2-Alkany l Acetates
甲基酮和 2-烷酰基乙酸酯的生物合成
  • 批准号:
    9118188
  • 财政年份:
    1992
  • 资助金额:
    $ 51.18万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了